Kamada Ltd. (NASDAQ:KMDA - Get Free Report) saw a significant growth in short interest in the month of May. As of May 31st, there was short interest totalling 48,500 shares, a growth of 57.0% from the May 15th total of 30,900 shares. Currently, 0.2% of the company's shares are short sold. Based on an average daily trading volume, of 95,400 shares, the days-to-cover ratio is presently 0.5 days.
Institutional Trading of Kamada
Hedge funds have recently modified their holdings of the business. Geode Capital Management LLC raised its stake in Kamada by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company's stock valued at $178,000 after buying an additional 1,549 shares during the last quarter. Aristides Capital LLC raised its position in shares of Kamada by 12.1% in the 4th quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company's stock worth $387,000 after purchasing an additional 6,850 shares during the last quarter. NewEdge Advisors LLC boosted its stake in Kamada by 54.2% in the 4th quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company's stock worth $143,000 after purchasing an additional 8,260 shares in the last quarter. JPMorgan Chase & Co. bought a new position in Kamada in the 4th quarter worth about $67,000. Finally, Trexquant Investment LP purchased a new stake in Kamada during the 1st quarter valued at about $82,000. Institutional investors own 20.38% of the company's stock.
Kamada Stock Performance
Shares of NASDAQ KMDA traded down $0.06 during trading on Friday, hitting $6.88. 109,223 shares of the company traded hands, compared to its average volume of 93,860. The firm has a market capitalization of $395.63 million, a price-to-earnings ratio of 24.57, a P/E/G ratio of 0.97 and a beta of 0.94. The business's fifty day moving average is $6.65 and its 200 day moving average is $6.73. Kamada has a fifty-two week low of $4.74 and a fifty-two week high of $9.16.
Kamada (NASDAQ:KMDA - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported $0.07 earnings per share for the quarter, hitting analysts' consensus estimates of $0.07. Kamada had a return on equity of 6.30% and a net margin of 9.92%. The business had revenue of $44.02 million for the quarter, compared to the consensus estimate of $154.06 million. On average, analysts predict that Kamada will post 0.23 EPS for the current year.
Analyst Upgrades and Downgrades
Several research firms have recently weighed in on KMDA. Sidoti upgraded shares of Kamada to a "hold" rating in a research report on Thursday, May 8th. HC Wainwright reissued a "buy" rating and issued a $11.00 price objective on shares of Kamada in a research report on Thursday, March 6th. Wall Street Zen raised Kamada from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, May 21st. Finally, Benchmark reaffirmed a "buy" rating and set a $15.00 target price on shares of Kamada in a research note on Thursday, May 15th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Buy" and an average price target of $14.67.
Check Out Our Latest Stock Report on KMDA
Kamada Company Profile
(
Get Free Report)
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Kamada, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kamada wasn't on the list.
While Kamada currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
